Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Vivimed Labs Ltd

    Vivimed has offices in Hyderabad, India, with five different functional manufacturing centres in proximity to the central office hub. Vivimed has a new state-of-the-art R&D faci

  • No Image
    Vivo Biotech Ltd

    Vivo Bio Tech is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guideli

  • No Image
    VKT Pharma Pvt Ltd

    VKT Pharma Pvt Ltd was incorporated as Potluri Builders Private Limited (PBPL) in the year 2006 in Andhra Pradesh and has been promoted by Mr. Potluri Ramesh Babu and Mrs Hima B

  • No Image
    Wanbury Ltd

    Wanbury Limited is a supplier of active pharmaceutical ingredients. Their products include metformin, tramadol, sertraline, paroxetine, mefenamic acid, diphenhydramine, glucosam